Sterling Capital Management’s Cytokinetics CYTK Stock Holding History

Sterling Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$207K	Sell	2,429 -1,211	-33%	-$87K	﹤0.01%	1217
2026 Q1	$240K	Sell	3,640 -2,502	-41%	-$159K	﹤0.01%	1101
2025 Q4	$390K	Sell	6,142 -1,091	-15%	-$67.9K	0.01%	1062
2025 Q3	$398K	Buy	7,233 +4,363	+152%	+$180K	0.01%	1065
2025 Q2	$94.8K	Buy	2,870 +1,045	+57%	+$36.3K	﹤0.01%	1365
2025 Q1	$73.3K	Sell	1,825 -1,507	-45%	-$69.3K	﹤0.01%	1349
2024 Q4	$157K	Buy	3,332 +2,964	+805%	+$154K	﹤0.01%	1331
2024 Q3	$19.4K	Buy	+368	New	+$20.5K	﹤0.01%	1481
2017 Q3	–	Sell	-52,388	Closed	-$634K	–	925
2017 Q2	$634K	Buy	+52,388	New	+$728K	0.01%	748

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's CYTK Position: Q2 2026 in Review

Sterling Capital Management reduced its Cytokinetics (CYTK) stake by 33% in Q2 2026, selling an estimated $87K and leaving 2,429 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #1217.

Sterling Capital Management first reported a position in CYTK in Q2 2017 and has held it in 9 quarters since. The position peaked at $634K in Q2 2017. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Sterling Capital Management held 2,429 shares of Cytokinetics worth $207K as of Q2 2026.
Sterling Capital Management sold 1,211 Cytokinetics shares in Q2 2026, an estimated $87K.
Cytokinetics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1217 holding.
Sterling Capital Management first reported a position in Cytokinetics in Q2 2017 and has held it in 9 quarters since.
Sterling Capital Management's Cytokinetics position peaked at $634K in Q2 2017.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.